Compare Ginkgo Bioworks Holdings Inc (DNA) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Johnson Controls International PLC — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while Johnson Controls International PLC trades at $157.44 (market cap $93.28B). The key difference: Johnson Controls International PLC is far larger — about 122.2× Ginkgo Bioworks Holdings Inc's market cap, and Johnson Controls International PLC pays a 1.04% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Johnson Controls International PLC for 65 Days on average.
| DNA | JCI | |
|---|---|---|
Market Cap | $763.64M | $93.28B |
Volume | 3,204,177 | 2,786,476 |
Sector | Health | Basic Materials |
52-Week High | $15.83 | $158.76 |
52-Week Low | $5.48 | $105.55 |
Typical Hold Time | 7 Days | 65 Days |
Enterprise Value | $865.59M | $102.12B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.00, up 13.34% today, with a bullish technical signal from moving averages. The company shows strong gross margins of 68.04% but remains unprofitable with a -219.6% net margin. Recent news includes a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnership expansions, though revenue declined to $132M in 2026.
DNA presents high risk with significant losses and cash burn, but analyst sentiment is divided with equal buy/sell ratings. Investment appeal hinges on future profitability from recent partnerships and government contracts, while current financials and negative cash flow pose substantial downside risk.
Johnson Controls (JCI) trades at $154.00, down 1.24% on the day, with strong technical momentum showing bullish moving averages and neutral oscillators. The company demonstrates robust fundamentals with Q3 2026 EPS of $1.42 beating expectations by 9.2% and raising full-year guidance. Revenue trends show recovery from $23.0B in 2024 to $23.6B in 2025, with net income margin expanding significantly to 13.94%. Recent news highlights strong demand for data-center thermal management systems and inclusion in AI industrial stock recommendations.
JCI presents a compelling investment case with 62% analyst buy ratings and $172.50 consensus price target offering 12% upside. The company benefits from strong AI-driven demand in thermal management systems, though elevated P/E of 43.38 and debt-to-asset ratio increasing to 26.06% warrant monitoring. Execution on raised FY26 guidance and data-center market expansion remain key catalysts for continued growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
